FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2347007079> ?p ?o ?g. }

• W2347007079 abstract "The incidence of acute kidney injury (AKI) in neonates in the intensive care units and neonatal intensive care (NICU) according Plotz et al. ranges from 8% to 22% [3]. According to Andreoli, neonatal death due to AKI in NICU amounts up to 10-61% [1]. It should be in the reasons of AKI emphasize.The role of certain drugs, which are widely used in modern neonatology: nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics (aminoglycosides, glycopeptides, carbapenems, 3rd generation cephalosporins), furosemide, enalapril, in contributing to AKI should be emphasized [2].To identify risk factors for acute kidney injury in neonates in intensive care units and intensive care.We performed a prospective observational case-control study of full-term newborns who were treated in the intensive care unit and neonatal intensive care of the Children's city hospital №1 Kazan and NICU №3 Children's Republican Clinical Hospital in 2011-2014 years.The study included 86 term infants in critical condition, who were hospitalized to the NICU on the first days of life, - the main group. The main criterion of AKI in neonates according to neonatal AKIN classification (2011) is a serum creatinine concentration ≥1.5 mg/dL. We subdivided the main group into two subgroups:subgroup I, AKI+ consisted of 12 term infants in critical condition with the serum creatinine level ≥ 1,5 mg/dL at the age of not younger than 48 hours after birth, which was 14% of all full-term newborns who were at the NICU;subgroup II, AKI- consisted of 74 term infants in critical condition with the serum creatinine level <1.5 mg/dL at the age of not younger than 48 hours after birth.The control group was formed by random sampling, it consisted of 26 somatically healthy term infants. We used conventional methods for evaluating renal function, and enzyme immunoassay (ELISA) for the urine biomarker of AKI, IL-18.Statistical analysis was performed using SPSS, Statistics 20, and the IBM and Microsoft Office Excel 2007. The study results were subjected to statistical analysis using parametric and non-parametric methods of analysis. We present the findings as arithmetic means (M) with, standard deviation (σ) and standard error of the mean (m) according to standard formulas.All children were admitted to primary and emergency care with subsequent transfer to the NICU at 1-2 days of life and further treatment in the department of pathology of newborns (DPN). The duration of hospitalization of infants at the NICU for the main group averaged 5,9 ± 0,44 days; at the DPN (subsequent stage of nursing) - 11,42 ± 0,51 days; for the subgroup I, AKI+ newborns these were 7,83 ± 1,23 days and 13,75 ± 3,34 days, respectively; for the subgroup II, AKI- newborns these were 5,58 ± 0,47 (3-30) and 11,04 ± 0,3 (0-47) days, respectively. Neonates received daily average of 16,5 ± 0,3 various medicines while at NICU and 9,1 ± 0,7 while at DPN. Overall, over the entire period of hospitalization neonates of the main group received on average 25,6 ± 1,8 medicines. Of these, 2,9 ± 0,4 drugs were antibiotics, possessing nephrotoxic properties (aminoglycosides, cephalosporins, carbapenems, fluoroquinolones). Children of the main group in 100% (n = 86) of cases were treated with 3rd generation cephalosporins (ceftriaxone, cephaperazone/sulbactam (sulperazon)), in 55% od cases (n = 47) - with aminoglycosides (amikacin, gentamicin), in 1% (n = 1) - with vancomycin, in 7% (n = 6) - with carbapenems. Diuretics were prescribed to 57% (n = 49) of infants. Often, patients were treated with a combination of nephrotoxic medications. Aminoglycoside were prescribed statistically more often to neonates of the subgroup I, than of the subgroup II (p <0.01). Diuretic drugs were used more frequently and for longer periods of time in neonates of the subgroup I (AKI+), than in newborns of the subgroup II (AKI-), namely, in 83% (n = 10) for 4,6 ± 1.34 days versus 53% of cases (n = 39) for 2.84 ± 0.49 days, respectively (p <0.05). IL-18 urine level in neonates of subgroup I (AKI+) was 2 times higher than that in neonates of the subgroup II (AKI-), and 13 times higher than in neonates of the control group.The fact that the IL-18 urine level increased with progression of kidney damage, caused by nephrotoxic therapy, suggests that a significant role in the development and progression of AKI in neonates at NICU belongs to drug therapy.Full-term newborns in intensive care units are at high risk of AKI when they are treated with aminoglycosides in combination with diuretics for longer than 4.5 days." @default.
• W2347007079 created "2016-06-24" @default.
• W2347007079 creator A5026622505 @default.
• W2347007079 creator A5027053524 @default.
• W2347007079 creator A5058873748 @default.
• W2347007079 date "2015-11-27" @default.
• W2347007079 modified "2023-09-27" @default.
• W2347007079 title "Acute kidney injury in neonatal intensive care: Medicines involved" @default.
• W2347007079 cites W2036938807 @default.
• W2347007079 cites W2056738418 @default.
• W2347007079 cites W2165637150 @default.
• W2347007079 doi "https://doi.org/10.3233/jrs-150669" @default.
• W2347007079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26639729" @default.
• W2347007079 hasPublicationYear "2015" @default.
• W2347007079 type Work @default.
• W2347007079 sameAs 2347007079 @default.
• W2347007079 citedByCount "17" @default.
• W2347007079 countsByYear W23470070792016 @default.
• W2347007079 countsByYear W23470070792017 @default.
• W2347007079 countsByYear W23470070792018 @default.
• W2347007079 countsByYear W23470070792019 @default.
• W2347007079 countsByYear W23470070792020 @default.
• W2347007079 countsByYear W23470070792021 @default.
• W2347007079 countsByYear W23470070792022 @default.
• W2347007079 crossrefType "journal-article" @default.
• W2347007079 hasAuthorship W2347007079A5026622505 @default.
• W2347007079 hasAuthorship W2347007079A5027053524 @default.
• W2347007079 hasAuthorship W2347007079A5058873748 @default.
• W2347007079 hasBestOaLocation W23470070791 @default.
• W2347007079 hasConcept C120665830 @default.
• W2347007079 hasConcept C121332964 @default.
• W2347007079 hasConcept C126322002 @default.
• W2347007079 hasConcept C177713679 @default.
• W2347007079 hasConcept C187212893 @default.
• W2347007079 hasConcept C2776376669 @default.
• W2347007079 hasConcept C2777091541 @default.
• W2347007079 hasConcept C2779234561 @default.
• W2347007079 hasConcept C2780306776 @default.
• W2347007079 hasConcept C2780472472 @default.
• W2347007079 hasConcept C2987404301 @default.
• W2347007079 hasConcept C536800656 @default.
• W2347007079 hasConcept C54355233 @default.
• W2347007079 hasConcept C61511704 @default.
• W2347007079 hasConcept C71924100 @default.
• W2347007079 hasConcept C86803240 @default.
• W2347007079 hasConceptScore W2347007079C120665830 @default.
• W2347007079 hasConceptScore W2347007079C121332964 @default.
• W2347007079 hasConceptScore W2347007079C126322002 @default.
• W2347007079 hasConceptScore W2347007079C177713679 @default.
• W2347007079 hasConceptScore W2347007079C187212893 @default.
• W2347007079 hasConceptScore W2347007079C2776376669 @default.
• W2347007079 hasConceptScore W2347007079C2777091541 @default.
• W2347007079 hasConceptScore W2347007079C2779234561 @default.
• W2347007079 hasConceptScore W2347007079C2780306776 @default.
• W2347007079 hasConceptScore W2347007079C2780472472 @default.
• W2347007079 hasConceptScore W2347007079C2987404301 @default.
• W2347007079 hasConceptScore W2347007079C536800656 @default.
• W2347007079 hasConceptScore W2347007079C54355233 @default.
• W2347007079 hasConceptScore W2347007079C61511704 @default.
• W2347007079 hasConceptScore W2347007079C71924100 @default.
• W2347007079 hasConceptScore W2347007079C86803240 @default.
• W2347007079 hasLocation W23470070791 @default.
• W2347007079 hasLocation W23470070792 @default.
• W2347007079 hasOpenAccess W2347007079 @default.
• W2347007079 hasPrimaryLocation W23470070791 @default.
• W2347007079 hasRelatedWork W1495373699 @default.
• W2347007079 hasRelatedWork W1597980115 @default.
• W2347007079 hasRelatedWork W1967448182 @default.
• W2347007079 hasRelatedWork W2016933146 @default.
• W2347007079 hasRelatedWork W2080954419 @default.
• W2347007079 hasRelatedWork W2101029826 @default.
• W2347007079 hasRelatedWork W2104070425 @default.
• W2347007079 hasRelatedWork W2335573319 @default.
• W2347007079 hasRelatedWork W2588333454 @default.
• W2347007079 hasRelatedWork W2611087731 @default.
• W2347007079 hasRelatedWork W2752404888 @default.
• W2347007079 hasRelatedWork W2807301101 @default.
• W2347007079 hasRelatedWork W2896830030 @default.
• W2347007079 hasRelatedWork W2956521455 @default.
• W2347007079 hasRelatedWork W2980366257 @default.
• W2347007079 hasRelatedWork W2990208874 @default.
• W2347007079 hasRelatedWork W3006444334 @default.
• W2347007079 hasRelatedWork W3013880874 @default.
• W2347007079 hasRelatedWork W3113854179 @default.
• W2347007079 hasRelatedWork W3184719786 @default.
• W2347007079 isParatext "false" @default.
• W2347007079 isRetracted "false" @default.
• W2347007079 magId "2347007079" @default.
• W2347007079 workType "article" @default.